IGF-1 LR3

IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) is an 83-amino-acid recombinant analog of human IGF-1 with two structural modifications: a 13-amino-acid N-terminal extension (MFPAMPLSSLFVN) and an arginine substitution at position 3 (Glu3 → Arg3) of the native IGF-1 sequence. These modifications were rationally designed to dramatically reduce binding affinity for IGF-binding proteins (IGFBPs) while preserving high-affinity binding to the IGF-1 receptor (IGF-1R) — the key signaling receptor through which IGF-1 exerts its growth-promoting and anabolic effects.

The Glu3Arg substitution disrupts the electrostatic salt bridges that mediate high-affinity IGFBP interaction — native IGF-1's Glu3 forms critical ionic contacts with positively charged residues in the IGFBP binding cleft, and replacing it with the positively charged arginine eliminates this interaction. The 13-amino-acid N-terminal extension provides additional steric hindrance, physically blocking IGFBPs from wrapping around the IGF-1 core domain. Together, these modifications reduce IGFBP affinity by approximately 90–95%, leaving the vast majority of administered IGF-1 LR3 as free, unbound ligand available for receptor engagement — in contrast to native IGF-1, where >99% is sequestered by circulating IGFBPs at any given moment.

Upon binding to IGF-1R (a transmembrane receptor tyrosine kinase), IGF-1 LR3 activates the same signaling cascades as native IGF-1: PI3K/Akt pathway — driving glucose uptake, protein synthesis, and cell survival; Ras/MAPK/ERK pathway — promoting cell proliferation and differentiation; and mTORC1 activation — the master regulator of anabolic metabolism. The extended 20–30 hour half-life (vs. 20–30 minutes for native IGF-1) is a direct consequence of reduced IGFBP clearance: IGFBPs normally shuttle IGF-1 to the kidneys for glomerular filtration, and without this sequestration, IGF-1 LR3 circulates in its free, active form for far longer. Research note: IGF-1R shares significant homology with the insulin receptor, and at high concentrations IGF-1 LR3 can activate insulin receptor isoforms — a cross-reactivity variable to control for in experimental design.

IGF-1 LR3 was developed in the 1990s by GroPep (Australia), building on the characterization of naturally occurring N-terminal IGF-1 variants in fetal and transformed cells that showed reduced IGFBP binding. The specific Long R3 design was optimized for cell-culture applications, where serum-containing media is rich in IGFBPs that sequester native IGF-1 and complicate dose-response studies. The analog's reduced IGFBP affinity allows researchers to control free-ligand concentration more precisely — a significant practical advantage in quantitative signaling assays.

While native recombinant human IGF-1 (mecasermin, Increlex) received FDA approval in 2005 for severe primary IGF-1 deficiency, IGF-1 LR3 itself has not been developed as a pharmaceutical. Instead, it has become a standard research tool in growth-factor biology — widely used in cell-culture models of myogenesis, neurogenesis, and receptor signaling, as well as in preclinical animal models studying muscle hypertrophy, tissue repair, and metabolic regulation. Its extended half-life and predictable free-ligand kinetics make it particularly suited to longitudinal studies where native IGF-1's rapid clearance would require continuous infusion.

Store lyophilized IGF-1 LR3 at -20°C to -80°C in a tightly sealed, desiccated container. As an 83-amino-acid recombinant protein with three disulfide bonds (Cys6-Cys48, Cys18-Cys61, Cys47-Cys52) that stabilize the characteristic IGF-fold tertiary structure, it is more structurally complex and correspondingly more sensitive than short synthetic peptides. Minimize temperature excursions and protect from moisture. Stability at -20°C exceeds 12 months; at -80°C, stability extends beyond 24 months. Short-term storage (up to 1 week) at 2–8°C is acceptable for lyophilized vials awaiting reconstitution.

After reconstitution, IGF-1 LR3 requires particularly careful handling. Reconstitute with sterile saline (0.9% NaCl) or bacteriostatic water containing 0.1% BSA as a carrier protein to minimize surface adsorption — the peptide's large hydrophobic surface area makes it prone to sticking to glass and plastic surfaces at low concentrations. The solution should be stored at 2–8°C and used within 7 days; the long peptide chain and critical disulfide bonds make it more susceptible to degradation than short synthetic peptides. Do not vortex or shake — mechanical stress can denature the tertiary structure. Do not freeze reconstituted solutions. For extended storage, aliquot and freeze at -80°C with carrier protein, avoiding repeat freeze-thaw.